Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Research analysts at Desjardins reduced their FY2024 earnings per share (EPS) estimates for Inovalis Real Estate Investment Trust in a report issued on Monday, November 11th. Desjardins analyst A. Leon now anticipates that the company will post earnings of $0.01 per share for the year, down from their prior forecast of $0.06.
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported C($0.29) earnings per share (EPS) for the quarter. The firm had revenue of C$3.52 million during the quarter.
Inovalis Real Estate Investment Trust Stock Performance
Inovalis Real Estate Investment Trust Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Featured Stories
- Five stocks we like better than Inovalis Real Estate Investment Trust
- Investing in the High PE Growth Stocks
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- 3 Small Caps With Big Return Potential
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Earnings Per Share Calculator: How to Calculate EPS
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.
